Product news

Share this article:

Eli Lilly announced that the FDA has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder in adults.

Novartis' Diovan (valsartan), an angiotensin receptor blocker, has been approved following a priority review by the FDA for the treatment of high blood pressure in children and adolescents ages six to 16.

Alcon announced that the FDA has approved Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION